Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

About the drawback of collagenase

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Pryor JP, Ralph DJ. Clinical presentations of Peyronie’s disease. Int J Impot Res. 2002;14:414–7.

    CAS  PubMed  Article  Google Scholar 

  2. 2.

    Arafa M, Eid H, El-Badry A, Ezz-Eldine K, Shamloul R. The prevalence of Peyronie’s disease in diabetic patients with erectile dysfunction. Int J Impot Res. 2007;19:213–7.

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Herati AS, Pastuszak AW. The genetic basis of Peyronie’s disease: a review. Sex Med Rev. 2016;4:85–94.

    PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    Goldstein I, Hartzell R, Shabsigh R. The impact of Peyronie’s disease on the patient: gaps in our current understanding. J Sex Marital Ther. 2016;42:178–90.

    PubMed  Article  Google Scholar 

  5. 5.

    Levine LA. Peyronie’s disease: a contemporary review of non-surgical treatment. Arab J Urol. 2013;11:278–83.

    PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Russell S, Steers W, McVary KT. Systematic evidence-based analysis of plaque injection therapy for Peyronie’s disease. Eur Urol 2007;51:640–7.

    PubMed  Article  Google Scholar 

  7. 7.

    Yafi FA, Pinsky MR, Sangkum P, Hellstrom WJG. Therapeutic advances in the treatment of Peyronie’s disease. Andrology. 2015;3:650–60.

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Levine LA. Seeking answers on the quest for effective nonsurgical treatment of Peyronie’s disease. Eur Urol 2007;51:601–3.

    PubMed  Article  Google Scholar 

  9. 9.

    Ralph D, Gonzalez-Cadavid N, Mirone V, et al. The management of Peyronie’s disease: evidence-based 2010 guidelines. J Sex Med. 2010;7:2359–74.

    PubMed  Article  Google Scholar 

  10. 10.

    Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012;187:2268–74.

    CAS  PubMed  Article  Google Scholar 

  11. 11.

    Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie’s disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199–207.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Ziegelmann MJ, Viers BR, McAlvany KL, Bailey GC, Savage JB, Trost LW. Restoration of Penile function and patient satisfaction with intralesional collagenase clostridium histolyticum injection for peyronie’s disease. J Urol 2016;195:1051–6.

    PubMed  Article  Google Scholar 

  13. 13.

    Yafi FA, Diao L, DeLay KJ, DeYoung L, Talib R, Alzweri L, et al. Multi-institutional prospective analysis of intralesional injection of collagenase clostridium histolyticum, tunical plication, and partial plaque excision and grafting for the management of Peyronie’s Disease. Urology. 2018;120:138–42.

    PubMed  Article  Google Scholar 

  14. 14.

    Goldstein I, Knoll LD, Lipshultz LI, Smith T, Kaufman GJ, McMahon CG. Changes in the effects of peyronie’s disease after treatment with collagenase clostridium histolyticum: male patients and their female partners. Sex Med. 2017;5:e124–e130.

    PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Abdel Raheem A, Capece M, Kalejaiye O, Abdel-Raheem T, Falcone M, Johnson M, et al. Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie’s disease using a new modified shortened protocol. BJU Int. 2017;120:717–23.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Capece M, Cocci A, Russo G, Cito G, Giubilei G, Cacciamani G, et al. Collagenase clostridium histolyticum for the treatment of Peyronie’s disease: a prospective Italian multicentric study. Andrology. 2018;6:564–7.

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Cocci A, Cito G, Urzì d, Minervini A, Di Maida F, Sessa F, et al. Sildenafil 25 Mg ODT + collagenase clostridium hystoliticum vs collagenase clostridium hystoliticum alone for the management of peyronie’s disease: a matched-pair comparison analysis. J Sex Med. 2018;15:1472–7.

    PubMed  Article  Google Scholar 

  18. 18.

    Cocci A, Russo G, Briganti A, Salonia A, Cacciamani G, Capece M, et al. Predictors of treatment success after collagenase clostridium histolyticum injection for peyronie’s disease: development of a nomogram from a multicentre single-arm, non-placebo controlled clinical study. BJU Int. 2018;122:680–7.

    CAS  PubMed  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Javier Romero-Otero.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

García-Gómez, B., Romero-Otero, J. About the drawback of collagenase. Int J Impot Res 33, 570–571 (2021).

Download citation


Quick links